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The genomics of advanced breast cancer (ABC) has been described through tumour tissue
biopsy sequencing, although these approaches are limited by geographical and temporal
heterogeneity. Here we use plasma circulating tumour DNA sequencing to interrogate the
genomic profile of ABC in 800 patients in the plasmaMATCH trial. We demonstrate diverse
subclonal resistance mutations, including enrichment of HER2 mutations in HER2 positive
disease, co-occurring ESR1 and MAP kinase pathway mutations in HR+HER2− disease that
associate with poor overall survival (p= 0.0092), and multiple PIK3CA mutations in HR+
disease that associate with short progression free survival on fulvestrant (p= 0.0036). The
fraction of cancer with a mutation, the clonal dominance of a mutation, varied between genes,
and within hotspot mutations of ESR1 and PIK3CA. In ER-positive breast cancer subclonal
mutations were enriched in an APOBEC mutational signature, with second hit PIK3CA
mutations acquired subclonally and at sites characteristic of APOBEC mutagenesis. This
study utilises circulating tumour DNA analysis in a large clinical trial to demonstrate the
subclonal diversification of pre-treated advanced breast cancer, identifying distinct muta-
tional processes in advanced ER-positive breast cancer, and novel therapeutic opportunities.
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Cancers evolve over time
1, and a metastatic cancer can har-
bour a different mutational profile following relapse com-
pared to the primary tumour2–8, in part due to genetic
events that can be selected by therapy as mechanisms of
resistance9,10. Traditionally tissue biopsies have been used to
characterise metastatic breast cancer, and large scale genomic
sequencing efforts have made remarkable progress in defining the
genomic landscape of metastatic breast cancer through tumour
tissue sequencing11–15. However, diagnostic tissue biopsies provide
a genomic snapshot limited to the primary tumour, and repeat
advanced disease biopsies are limited by sampling bias, in particular
in the presence of spatial heterogeneity, where individual metastases
may develop different resistance mechanisms16–18, and are
invasive19. Circulating tumour DNA (ctDNA), released into the
systemic circulation following tumour cell death20,21, is theoretically
an admixture of tumour DNA from heterogeneous metastatic sites,
and may more fully describe tumour heterogeneity22.
In metastatic sequencing studies of advanced breast cancer, the
most major differences to primary breast cancer have been
identified in hormone receptor (HR+) positive breast cancer12. In
HR+ breast cancer oestrogen receptor mutations (ESR1)23, MAP
kinase (MAPK) pathway mutations11,24, and transcription factor
alterations11 such as ARID1A mutations11,25,26, are acquired as
mechanism of resistance to prior endocrine therapy. In single site
biopsies, these routes to endocrine therapy resistance are
mutually exclusive11. Tumour autopsy studies have demonstrated
the substantial prevalence of geographical heterogeneity, where
individual metastases may have different genomic profiles27,
raising uncertainty over whether genomics studies based on single
site biopsies have captured the full picture of advanced breast
cancer genomics. In triple negative and HER2 positive (HER2+ )
breast cancer, no major changes have been identified in the
genomics of advanced breast cancer, compared with primary
breast cancer11,12.
Here we define the genomic profile of metastatic breast cancer
using ctDNA sequencing from patients within plasmaMATCH, a
prospective platform trial leveraging ctDNA analysis in patients
with metastatic breast cancer for which the primary outcomes
have been published28. In this ad-hoc analysis we investigate how
the profile of somatic genetic alterations in ctDNA differs from
that obtained by tumour tissue sequencing. Using the rich clinical
data set associated with the clinical trial, we explore the clinical
and pathological associations of advanced breast cancer geno-
mics, and define the processes that generate the genomic diversity
of metastatic breast cancer.
Results
PlasmaMATCH circulating tumour DNA sequencing. Between
21st December 2016 and 26th April 2019, 1,051 patients were
enroled into plasmaMATCH (Supplementary Fig. 1a). Baseline
pre-treatment ctDNA targeted sequencing results were available
for 800 patients28 (available in Supplementary Data 1). Of the
patients with available targeted sequencing, 64.4% (N= 515) had
hormone receptor positive (HR+ ) HER2 negative (HER2-, lack
of HER2 over-expression and/or gene amplification) disease, 9.1%
(N= 72) were HER2 positive, and 17.3% (N= 138) had triple-
negative breast cancer (TNBC, Supplementary Table 1).
Plasma samples were sequenced by duplex error corrected
sequencing with a clinical diagnostic panel targeting 74 cancer
genes (Supplementary Fig. 1b). Overall, 92.9% of patients were
found to have at least one ctDNA alteration. The most frequently
altered genes were TP53 (44.1%), PIK3CA (34.9%), ESR1 (33.1%),
GATA3 (11.0%), ARID1A (7.8%) and PTEN (6.9%, Fig. 1a). The
frequency of TP53, PIK3CA, ESR1 and GATA3 mutations varied
according to breast cancer subtype (Fig. 1b) as previously
described11,12,29. We also identified novel subtype associations,
withHER2 (also known as ERBB2) mutations enriched in HER2+
disease compared to HR+HER2- (q= 0.05) and TNBC (q=
0.005, Fig. 1b). HR+HER2- disease had significantly more
pathogenic alterations per patient than HER2+ disease (3.0 vs
2.2, p= 0.03) and TNBC (3.0 vs 1.8, p < 0.0001, Fig. 1c).
Copy number (CN) alterations in ctDNA were also associated
with breast cancer subtype (Fig. 1d and Supplementary Fig. 2),
with CN alterations in MYC, PIK3CA, EGFR, CCNE1, CDK6,
BRAF and MET more common in TNBC (q= 0.01, q < 0.0001,
q= 0.001, q < 0.0001, q= 0.0003, q= 0.0002 and q= 0.01,
respectively, Fig. 1d). FGFR1 and CCND1 CN alterations were
more common in HR+HER2- breast cancer (q= 0.01 and q <
0.001, respectively). A small subset (1.7%) of HR+HER2- and
TNBC, assessed in prior tissue, had HER2 amplification detected
in ctDNA (Fig. 1d), likely reflecting acquisition of HER2
amplification.
We assessed the sensitivity of targeted sequencing to identify
droplet digital PCR (ddPCR) mutation calls in targetable hotspots
within PIK3CA, HER2, AKT1 and ESR1. Within the 682 patients
who underwent ctDNA testing with both technologies, the
targeted sequencing demonstrated a high sensitivity of 90.9% in
identifying mutations. For mutations with ddPCR allele fre-
quency <1%, the targeted panel sensitivity was 80.9% (Supple-
mentary Fig. 3).
Polyclonal genomic resistance in ctDNA. Mutated genes showed
tendency for patterns of co-enrichment and mutual exclusivity.
PIK3CA and AKT1 alterations were mutually exclusive (q=
0.001)11,29, and ESR1 and TP53 alterations were mutually
exclusive (q < 0.0001, Fig. 2a)12,30,31. In agreement with meta-
static tissue sequencing datasets11, NF1 and TP53, and PIK3CA
and HER2 tended to co-occur (p= 0.05 and p= 0.02, respec-
tively, Fig. 2a). Similar patterns were noted in HR+HER2- dis-
ease where PIK3CA and GATA3 (p= 0.03) and ESR1 and TP53
(p= 0.002) tend to be mutually exclusive, suggesting distinct
mechanisms of endocrine resistance in TP53 mutant cancer.
PIK3CA and KRAS alterations (p= 0.02), and PTEN and NF1 (p
= 0.02) alterations were found to be co-enriched (Supplementary
Fig. 4)
In metastatic tissue sequencing datasets, alterations within the
MAPK pathway and ESR1 mutations are mutually exclusive in
HR+HER2- disease11. In contrast, in ctDNA sequencing MAPK
alterations were more common in patients with ESR1 mutations
overall (p= 0.001, Fig. 2b), and in HR+HER2- breast cancer (p
= 0.02, Fig. 2b). Allele fractions of ESR1 and MAPK alterations in
the same patient did not overlap, indicating these mutations
existed in different clones (Supplementary Fig. 5). Furthermore,
MAPK alterations were substantially enriched in patients with
polyclonal ESR1 mutations as compared to single ESR1 mutations
(39.3% versus 19.6% respectively, p= 0.0004, Fig. 2b), identifying
a subset of oestrogen receptor (ER) positive breast cancers that
develop polyclonal genomic resistance (Fig. 2c). Overall survival
in patients with HR+HER2- disease and alterations in both
ESR1 and MAPK pathway was 7.9 months and in patients wild-
type for both ESR1 and MAPK pathway was 18.5 months
(Fig. 2d), with polyclonal resistance associating with poor
survival.
Circulating versus tissue based genomic profiling. We investi-
gated how the profile of somatic genetic alterations in breast
cancer ctDNA compared to that obtained by tissue sequencing, in
a large metastatic breast cancer tissue sequencing dataset (MSK-
IMPACTTM)11 (Supplementary Tab. 2). In HR+HER2- disease,
we identified enrichment for pathogenic alterations in ESR1 and
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TP53 in ctDNA (q < 0.0001 and q= 0.0009, respectively, Fig. 2e).
Mutations in BRAF were identified in ctDNA sequencing in 1.6%
(8/515) HR+HER2- cancers, not previously described in tissue
sequencing, with activating mutations (G466X, G469X, D594N)
and no V600E mutations. Otherwise, the mutational profile
identified in ctDNA and tissue across different breast cancer
subtypes was broadly similar (Fig. 2e). Microsatellite instability
was identified in 1.1% of advanced breast cancers.
Comparing ctDNA-derived mutations to a primary treatment-
naive breast cancer tissue sequencing dataset (TCGA)29,
substantial differences were observed (Supplementary Fig. 6)11,13.
PIK3CA mutations were less common in metastatic HR+HER2-
disease (q < 0.0001), whilst ESR1, AKT1 and alterations in the
epigenetic regulator ARID1A were enriched (q < 0.0001, q= 0.006
and q= 0.04, respectively, Supplementary Fig. 6) compared to
primary. The ctDNA genomic profile of advanced TNBC was
similar to that of primary TNBC tissue sequencing.
Clinical and pathological genomic associations and HER2
mutations in HER2 positive breast cancer. Using the rich
clinical trial data available, we explored the clinical and patho-
logical associations of ctDNA mutations, and the maximum
variant allele frequency (mVAF) as a proxy of ctDNA purity
(Fig. 3a). The number of lines of treatment was associated with
increased number of SNVs/indels and mVAF (Fig. 3a), and soft
tissue/nodal disease with lower mVAF (13.2 vs 8.0, q= 0.002,
Fig. 3a). Patients without a ctDNA alteration were significantly
more likely to have had fewer lines of treatment (p= 0.02, Sup-






















































































































































































Fig. 1 Mutation profile of advanced breast cancer determined by ctDNA sequencing. a Mutational profile of advanced breast cancer determined by
ctDNA targeted sequencing of 800 patients in the plasmaMATCH trial. Displayed are mutations and indels likely to be pathogenic (“Methods”),
summarised by gene for each patient. Top bar refers to total counts of pathogenic mutations per patient. Right, variant classification of the alterations within
each gene. FS, frameshift; IF, in-frame. b Breast cancer subtype association of the most frequently mutated genes within patients with known phenotype
(HR +HER2- N= 515, HER2+ N= 72, TNBC N= 138). Comparison with false discovery corrected two-sided Fisher’s exact tests (TP53: HR+HER2- vs
HER2+ q= 0.003, HR+HER2- vs TNBC q < 0.0001, HER2+ vs TNBC q= 0.04; PIK3CA: HR+HER2- vs TNBC q < 0.0001, HER2+ vs TNBC q= 0.0008;
ESR1: HR+HER2- vs HER2+ q < 0.0001, HR+HER2- vs TNBC q < 0.0001, HER2+ vs TNBC q= 0.008; GATA3: HR+HER2- vs TNBC q < 0.0001; HER2:
HR+HER2- vs HER2+ q= 0.05, HER2+ vs TNBC q= 0.005). ns, not significant. c Patient mutation frequency split by breast cancer subtype, overall and
likely pathogenic mutations in patients with known phenotype (HR+HER2- N= 515, HER2+ N= 72, TNBC N= 138). Data are presented as a violin plot
with inlayed boxplot, where the middle line is the median, the lower and upper hinges represent the 25th and 75th centiles respectively and the whiskers
extend from the hinge to the smallest and largest value, respectively, no further than 1.5 x IQR (interquartile range) from the lower or upper hinge. Data
outside of these ranges are plotted individually. Comparison of likely pathogenic mutations with false discovery corrected two-sided pairwise Kruskal-Wallis
test, HR+HER2- vs HER2+ q= 0.03, HR+HER2- vs TNBC q < 0.0001. d Frequency of copy number increases in ctDNA split by breast cancer subtype in
patients with known phenotype (HR+HER2- N= 515, HER2+ N= 72, TNBC N= 138). Comparison with false discovery corrected Chi-squared tests (MYC
q= 0.01, PIK3CA q < 0.0001, FGFR1 q= 0.01, EGFR q= 0.001, HER2 q < 0.0001, CCNE1 q < 0.0001, CCND1 q < 0.001, CDK6 q= 0.0003, BRAF q= 0.0002,
MET q= 0.01). FS, frameshift; IF, in-frame.
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lobular than in ductal breast cancer (Fig. 3b, p < 0.0001)32,33.
HER2 mutations were found more commonly in HER2+ cancers
with increasing lines of HER2 directed therapy (p= 0.04, Fig. 3c),
suggesting acquisition of HER2 mutations as a mechanism of
resistance to prior HER2 targeted therapies, and identifying a
potential novel treatment strategy for HER2+ resistant disease.
We validated rare and hotspot HER2 mutations calls by ddPCR,
with 91.7% (22/24) of mutations validating (Supplementary
Fig. 7). RB1 mutations were modestly enriched in patients with
HR+HER2- disease and prior CDK4/6 inhibitor exposure, with
no evident differences in genomic profile post mTOR inhibition
with everolimus (Supplementary Fig. 8)34. Patients with tissue
HER2 negative disease (N= 605) had a significantly lower mean
adjusted ERRB2 copy number in ctDNA compared to those with
tissue HER2 positive disease (2.2 vs 9.9, p < 0.0001, Fig. 3d). A
plasma HER2 copy number threshold of >2.0 had a sensitivity of
50% (95% CI 37.92–62.08) and specificity of 98% (95% CI
96.77–98.98) in identifying the tissue-based HER2 status defined
on the most recent tissue sample—advanced or archival primary
if not available (Fig. 3d).
Alterations within TP53, GATA3, ESR1 and PIK3CA showed a
tendency for organotropism (Fig. 4a). Bone disease was positively
associated with ESR1 and GATA3 alterations (q < 0.0001 and q=
0.0009, respectively), and TP53 negatively associated (q= 0.02).
Liver disease showed a positive association with ESR1 alterations
(q < 0.0001) but a negative association with TP53 alterations (q=
0.002). In HR+HER2- disease ESR1 mutations were positively
associated with liver and bone disease (q= 0.004 and q= 0.02,
respectively, Fig. 4b). After correction for multiple testing, no
genes demonstrated a significant pattern of organotropism in
TNBC (Fig. 4b).
APOPEC mutational signature in subclonal mutations of ER
positive breast cancer. To investigate the clonal dominance of
individual mutations, we calculated the cancer fraction of each
TP53 PIK3CA ESR1 GATA3 ARID1A PTEN HER2 NF1 AKT1
AKT1 0.001




GATA3 0.004 0.044 0.003
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Fig. 2 Polyclonal resistance with co-enrichment of MAPK pathway and ESR1 mutations in advanced breast cancer. a Association analysis for most
frequent mutated genes with overall Fisher’s exact test two-sided p-values. Green genes showing mutual exclusivity, and purple showing co-occurrence
with dark colours indicating significance following false discovery correction. b Frequency of MAPK pathway alterations comparing ESR1 mutant (77/265)
vs ESR1 wild-type cancers overall (100/535) (left), ESR1 mutant (66/226) vs wild-type (59/289) in HR+HER2- cancers (middle), and within ESR1 mutant
cancers between patients with single (27/138) and polyclonal ESR1 mutations (50/127) (right). p-values from two-sided Fisher’s exact test. c Example of
polyclonal genomic resistance in a patient with multiple MAPK pathway and ESR1 mutations in ctDNA. Blue indicate dominant mutations with cancer
fraction, and green subclonal mutations with cancer fraction. d Overall survival (OS) in patients with HR+HER2- disease who entered a treatment cohort
in plasmaMATCH divided by combined ESR1 and MAPK pathway mutation status. ESR1WT and MAPK WT, median 18.5 months, hazard ratio (HR) -. ESR1
mt and MAPK WT, median 17.7 months, HR 0.82, 95% confidence interval (CI) 0.40 to 1.69. ESR1 WT and MAPK mt, median 10.1 months, HR 1.65, 95%
CI 0.56 to 4.88. ESR1 mt and MAPK mt, median 7.9 months, HR 1.65, 95% CI 0.84 to 3.23. p-value from log-rank test. HR > 1 indicate worse OS for that
group. WT, wild-type; mt, mutant. e Mutational profile of ctDNA in plasmaMATCH (N= 725 patients with known breast cancer subtype) compared to
published large metastatic breast cancer tissue sequencing dataset (MSKCC, N= 715 patients with known breast cancer subtype)11. Red dots indicate
significant change in frequency after false discovery adjusted two-sided Fisher’s exact test (HR+HER2-: ESR1 q < 0.0001, TP53 q= 0.0009). Included are
genes with an incidence 1.5% in both data sets.
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alteration (“Methods”, Fig. 5a). Mutations within AKT1, PIK3CA
and GATA3 were significantly more likely to be dominant (q <
0.0001, q < 0.0001, q= 0.0003, respectively), while alterations in
ESR1, SMAD4 and KRAS were significantly more likely to be
subclonal (q < 0.0001, q= 0.02 and q < 0.0001, respectively). ESR1
mutations were frequently polyclonal (50%, Fig. 5b), occurring
almost exclusively in trans (93%, Supplementary Fig. 9). The
proportion of dominant to subclonal mutations did not
significantly alter with time from diagnosis of primary breast
cancer (Supplementary Fig 10).
To investigate the mutational processes promoting diversity in
advanced breast cancer, we aggregated dominant and subclonal
alterations by subtype, and performed bootstrap mutational signature
analysis (“Methods”). In HR+HER2- disease, subclonal alterations
were substantially enriched in signature 13 (APOBEC-related











































































































































































































































































































































































































































































NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-22605-2 ARTICLE
NATURE COMMUNICATIONS |         (2021) 12:2423 | https://doi.org/10.1038/s41467-021-22605-2 |www.nature.com/naturecommunications 5
less common in subclonal mutations. In contrast, in TNBC disease
subclonal alterations were substantially enriched in age related
signature 1 (Fig. 5c). Similarly, subclonal mutations in HR+HER2
+ disease were enriched for signatures 2 and 13, whilst subclonal
mutations in HR-HER2+ disease were enriched for age related
signature 1 (Supplementary Fig. 11). A second mutational signature
analysis package designed specifically for targeted sequencing data35
was utilised to corroborate findings, demonstrating broadly similar
results (Supplementary Fig. 12).
PIK3CA double mutations at APOBEC mutagenesis sites.
Within individual genes, ESR1 and PIK3CA hotspot mutations
showed significant variation in clonal dominance (both p <
0.0001, Fig. 6a). ESR1 mutations D538G and Y537S were more
dominant than other ESR1 mutations. PIK3CA mutations
H1047R/L, N345K and G1049R were dominant, whilst classical
hotspot mutations E545K and E542K were of lower clonal
dominance, and multiple novel PIK3CA mutations were highly
subclonal (Fig. 6a and Supplementary Fig. 13a). We validated the
novel subclonal PIK3CA mutations calls by plasma ddPCR, with
80.0% of mutations revalidating (Supplementary Fig. 13b). Novel
PIK3CA mutations occurred almost exclusively in the presence of
other hotspot mutations, which were frequently present at sub-
stantially high clonal fractions (Fig. 6b and Supplementary
Fig. 14), suggesting acquisition of second PIK3CA mutations.
In HR+HER2- PIK3CA mutant disease, 23% (47/202) of
patients had multiple PIK3CAmutations (Supplementary Fig. 15).
The second PIK3CA mutation was frequently subclonal, display-
ing single nucleotide substitutions and mutation contexts
consistent with those of APOBEC mutagenesis (Fig. 6c, d). The
same predisposition did not occur in PIK3CA mutant TNBC
disease, where dominant and subclonal alterations were equally
likely to occur at APOBEC sites (Fig. 6d). In plasmaMATCH,
patients with ESR1 mutations in ctDNA were enroled in a cohort
of extended dose fulvestrant, an oestrogen receptor down-
regulator (Supplementary Fig. 1). Patients with multiple PIK3CA
mutations had worse progression free survival on fulvestrant
compared to patients with a single PIK3CA mutation or PIK3CA
wild-type (Fig. 6e).
Discussion
Utilising the largest prospective ctDNA genomic profiling study
of patients progressing with advanced breast cancer, we identify
substantial novel features of advanced breast cancer with ctDNA
sequencing, demonstrating the ability of ctDNA analysis to dis-
sect spatial heterogeneity and subclonal sampling. In HR+HER-
breast cancer ctDNA analysis demonstrates divergent routes to
endocrine resistance in individual patients, suggesting that dif-
ferent metastases may develop divergent mechanisms of resis-
tance. Prior advanced tissue sequencing studies demonstrated
mutual exclusivity of ESR1 mutations and MAPK pathway
Fig. 3 Clinical and pathological associations of breast cancer mutation profile. a Association of number of mutations (SNVs/indels, left) and the
maximum variant allele frequency (mVAF, right, as a proxy of ctDNA purity) with indicated clinical and pathological features. p values from pairwise two-
sided Kruskal–Wallis test with correction for multiple testing (number of mutations: HR+HER2- vs TNBC q= 0.008; 0 vs ≥5 lines of treatment q=
0.0005, 1–2 vs ≥5 lines of treatment q= 0.0005; 0 vs ≥3 lines of chemotherapy q= 0.003. mVAF: 0 vs ≥5 lines of treatment q= 0.03, 1–2 vs ≥5 lines of
treatment q= 0.006; 0 vs 1–2 lines of chemotherapy q= 0.003, 0 vs ≥3 lines of chemotherapy q= 0.0003; soft tissue/nodal vs visceral disease q=
0.002). MBC, metastatic breast cancer; CTx, chemotherapy; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma. b Association of clinical and
pathological features with pathogenic alterations in the four targetable genes in plasmaMATCH: PIK3CA, ESR1, HER2 and AKT1. p-values from Chi-squared
test (PIK3CA: histological subtype p < 0.0001, lines of treatment p= 0.006; ESR1: histological subtype p < 0.0001, lines of treatment p < 0.0001, disease
site p= 0.003; HER2: histological subtype p= 0.004, primary breast cancer subtype p < 0.0001). c HER2 mutation incidence in patients with HER2+
cancer, by line of therapy. 0–1 lines of therapy mutation incidence 7.3% (3/41) and 2–3 lines of therapy mutation incidence 25% (8/32) HER2mutations, p
= 0.04, Chi-squared test. mt, mutant; wt wild-type. d) Adjusted HER2 copy number (CN) in targeted sequencing, in patients with tissue assessed HER2+
(amplified, N= 72) and HER2- (non-amplified, N= 605) cancers. (left) receiver operator curve of adjusted HER2 plasma copy number, (right) HER2 plasma
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Fig. 4 Organotropism of mutations in advanced breast cancer. a Association of mutations in indicated genes with sites of metastasis. p-values from false
discovery corrected two-sided Fisher’s exact test (ESR1: bone q < 0.0001, liver q < 0.0001, lymph node q= 0.0001; GATA3: bone q= 0.0009; PIK3CA:
lymph node q= 0.005; TP53: lymph node q= 0.002, liver q= 0.002, bone q= 0.02). b Association of mutations in indicated genes with sites of
metastasis in left HR+HER2- and right TNBC. p-values from false discovery corrected two-sided Fisher’s exact test (HR+HER2- ESR1: liver q= 0.004,
bone q= 0.02).
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alterations in individual metastatic sites11. In contrast, we
demonstrate ESR1 mutations co-existing with MAPK pathway
alterations (Fig. 2b), in particular in patients with polyclonal ESR1
mutations (Fig. 2b, c), with polyclonal resistance associated with
poor overall survival (Fig. 2d). We report the sub-clonal structure
of advanced breast cancer, and whilst many classic cancer driver
genes are shown to be dominant in the cancer (present in all or
most tumour cells), multiple other cancer genes are frequently
subclonal. We further demonstrate that even within individual




















































































































































Fig. 5 Clonal dominance and mutational signatures in dominant and subclonal mutations. a Cancer fractions of mutations in indicated genes, ordered by
mean cancer fraction (N= 1974 mutations with assessable cancer fractions). The mean value is indicated with a blue line. *indicates significant difference
in cancer fraction compared to remaining cases, false discovery corrected two-sided Wilcoxon signed-rank test (AKT1 q < 0.0001, PIK3CA q < 0.0001,
GATA3 q= 0.0003, ESR1 q < 0.0001, SMAD4 q= 0.02, KRAS q < 0.0001). Cancer fraction—allele fraction of the mutation relative to the maximum somatic
allele fraction in the sample. b Proportion of mutations that occur as a single versus multiple mutations per patient in indicated genes. *indicates significant
difference in proportion to single to multiple mutations in the gene compared to remaining cases, false discovery corrected two-sided Fisher’s exact test
(AKT1 q= 0.0009, CDH1 q= 0.05, GATA3 q < 0.0001, ESR1 q < 0.0001). c Bootstrap mutational signature analysis on aggregated mutations from all HR+
HER2- (left, clonally dominant mutations N= 328, subclonal mutations N= 968) and TNBC (right, clonally dominant mutations N= 121, subclonal
mutations N= 190) breast cancers, for dominant and subclonal mutations. Signature contributions for clonal versus subclonal alterations were ascertained
using deconstructSigs and compared using a two-sided Mann–Whitney U-test. Signatures with significant difference in signature contribution and no
overlap in interquartile range are identified with the p-value (HR+HER2-: signature 3 p < 0.0001, signature 13 p < 0.0001; TNBC: signature 1 p < 0.0001,
signature 5 p < 0.0001, signature p < 0.0001).
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clonal dominance with some mutations being highly dominant
whilst others are frequently subclonal.
We identify a number of new therapeutic approaches for
advanced breast cancer. We identify acquired genomic changes in
advanced HER2+ breast cancer, with HER2 mutations selected
subclonally though increasing lines of HER2 directed therapies
(Fig. 3c). This finding suggests a novel mechanism of resistance to
HER2 directed therapy in HER2 positive breast cancer, empha-
sising the need to investigate whether these cancers would benefit
specifically from HER2 tyrosine kinase inhibitors that inhibit
mutant HER236. In HR+HER2- breast cancer we identify BRAF
mutations previously not described in advanced breast cancer,
with emergence of known activating BRAF mutations identified
in lung cancer (G466X, G469X, D594N)37 and no V600E muta-
tions. A small subset (1.1%) of advanced breast cancers have
microsatellite instability in ctDNA sequencing, potentially iden-
tifying patients that may benefit from immune checkpoint
antibodies38. We also show that HER2 amplification can be
identified with high specificity in ctDNA, although sensitivity
remains limited favouring recurrent disease biopsy for repeat
HER2 testing to identify the small minority of patients who
acquire HER2 amplification at relapse. However, for patients who
have disease sites that are not suitable for recurrent disease
biopsy, ctDNA testing may present an opportunity to screen for
acquisition of HER2 amplification (Fig. 3d). Detection of HER2
amplification in plasma in other tumour types has identified
responders to HER2 directed therapy39,40.
Different mutational processes drive diversity in breast cancer
subtypes. HR+ advanced breast cancer is characterised by sub-
clonal mutations in part generated by APOBEC mutagenesis. We
dominant subclonal
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Fig. 6 Subclonal multiple PIK3CA mutations and resistance to fulvestrant. a Cancer fractions of individual pathogenic hotspot mutations in indicated
gene, including hotspots with at least 3 mutations in the overall data set or for any indel. p-value from two-sided Kruskal–Wallis test for variation in cancer
fraction across mutations in gene (ESR1 p < 0.0001, PIK3CA p < 0.0001). b Analysis of patients with H1047R (left, N= 39) and E726K (right, N= 26) dual
pathogenic PIK3CA mutations, with linkage of cancer fraction of indicated PIK3CA mutation with the other PIK3CA mutation present in the same patient.
The p-values indicated are derived from two-sided Mann–Whitney U-tests (H1047R p < 0.0001, E726K p= 0.02). c Analysis of individual recurrent
hotspot mutations in HR+HER2- PIK3CA mutant disease (N= 202) with mean cancer fraction, proportion of mutations detected as a single PIK3CA
mutation, and indication of whether the mutation occurs at an APOBEC consensus site. Mutations occurring at least 3 times in the HR+HER2- disease
dataset included. Cancer fraction and proportion single mutations is lower at APOBEC sites, P < 0.001, two-sided Fisher’s exact test both comparisons. d
Proportion of PIK3CA mutations that occur at APOBEC consensus sites, by cancer subtype (HR+HER2- N= 197, TNBC N= 21), and clonally dominant (N
= 194 mutations within HR+HER2- breast cancers and N= 16 within TNBC breast cancers) versus subclonal PIK3CA mutation (N= 82 mutations within
HR+HER2- breast cancers and N= 9 within TNBC breast cancers). P-value from two-sided Fisher’s exact test. ns, not significant. e Progression free
survival (PFS) in patients on fulvestrant in treatment cohort A in plasmaMATCH divided by PIK3CA mutation status. Cohort A patients with available
sequencing data included (78/84). PIK3CA WT, median 2.4 months, HR -. PIK3CA single mt, median 2.4 months, HR 0.71, 95% CI 0.41 to 1.22. PIK3CA
multiple mt, median 1.6 months, HR 3.15, 95% CI 0.88 to 11.33. p-value from log-rank test. HR > 1 indicates worse PFS for that group. WT, wild-type; mt,
mutant.
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hypothesise that APOBEC is activated during prior endocrine
therapy for advanced cancer, and that this may edit PIK3CA to
generate frequent second hit novel mutations12, resulting in
hyperactivation of PI3K signalling41 and resistance to fulvestrant
endocrine therapy (Fig. 6e). We performed a mutational signature
analysis to differentiate drivers of clonal and subclonal disease.
Relative to the broad sequencing approaches of whole-exome and
whole-genome sequencing, targeted panels sequence selected
areas of interest and as such cover less of the genome, which may
limit mutational signature analysis on this data. However, our
finding of APOBEC mutations in HR+HER2- subclonal muta-
tions concurs with tissue biopsy sequencing studies12,15, and
confirms that this process contributes to the subclonal diversity of
HR+ advanced breast cancer. PIK3CA mutations vary in clonal
dominance (Fig. 6a), and future research will need to investigate
whether this variation in subclonality effects response to PI3
kinase inhibitors in the clinic42. The poly-clonal nature of
endocrine resistance likely substantially challenges attempts to
treat endocrine resistant disease. Taken together, our findings
emphasise the importance of investigating upfront combination
approaches to prevent endocrine resistance. Such approaches
could possibly include APOBEC or PI3K pathway inhibitors.
In TNBC, we identified that subclonal diversity is associated
with age related mutational signatures, suggesting a lack of spe-
cific processes driving subclonality, and potentially suggesting
early diversification of metastatic TNBC. We note that patients
with TNBC in this series were relatively infrequently treated with
targeted therapies or immunotherapy, and it is possible that in the
future specific mutational processes selected by targeted therapies
will shape subclonality in TNBC. Given the limitations of
mutational signature analysis undertaken in targeted sequencing
data, these findings require corroboration with whole-exome or
whole genome sequencing data.
There are important limitations to our study and considera-
tions to make when understanding the utility of ctDNA in clinical
practice. Matched germline blood was not simultaneously
sequenced in our study. A small subset of mutations we report in
TP53 and KRAS might have originated from clonal hematopoesis
as opposed to the cancer43. To confidently exclude clonal
hematopoesis future research could involve paired germline
sequencing, or stringent criteria for variant identification in genes
affected by clonal hematopoesis.
Consideration should also be given to the likelihood of false
negative results, with some patient groups less likely to shed
ctDNA (Fig. 3a), such as those with low burden nodal disease
with fewer lines of therapy, where ctDNA may not fully char-
acterise the mutations present. Our study also emphasises that
copy number detection is of limited sensitivity in plasma, and for
tumour types where copy number events dominate tumour
biology alternative approaches of genotyping are required29.
More comprehensive approaches to genotyping ctDNA such as
whole exome sequencing could extend our observations. How-
ever, to detect subclonal mutations such approaches will still
require error correction, and such approaches are likely to be
substantially expensive and likely beyond routine clinical
application.
Our findings illustrate the substantial clinical and research
potential of ctDNA analysis in defining clonal architecture in
cancer, identifying subclonal resistance mutations not appreciable
by single site metastatic tumour biopsies, establishing patterns of
clonal dominance and characterising the mutational processes
that drive diversification of metastatic breast cancer.
Methods
Patient consent and blood sampling. Patients were enroled prospectively to the
plasmaMATCH trial (NCT03182634). plasmaMATCH was co-sponsored by the
Institute of Cancer Research and the Royal Marsden National Health Service
(NHS) Foundation Trust, London, UK, and approved by a Research Ethics
Committee (16/SC/0271). All participants gave written informed consent before
registration for ctDNA testing. ctDNA testing was undertaken using two ortho-
gonal techniques, droplet digital PCR (ddPCR) and error corrected targeted
sequencing. Positive mutation status allowed entry into one of five treatment
cohorts with a matched targeted therapy (Supplementary Fig. 1a). Patients were
eligible to enrol for ctDNA testing within plasmaMATCH if they had advanced
breast cancer (ABC) with measurable disease, had progressed on prior therapy for
ABC, or relapsed within 12 months of adjuvant chemotherapy, and (following an
amendment partway through the trial) had not had more than two lines of che-
motherapy for ABC (Supplementary Fig. 1a). Breast cancer subtype was defined
using standard clinical ER, PR and HER2 testing on the most recent tissue sample
(metastatic, or if not available, the archival primary).
ctDNA testing was undertaken prospectively within the trial by droplet digital
PCR (ddPCR) (Supplementary Fig. 1b). Partway through the trial, ctDNA testing
was also undertaken prospectively by targeted sequencing, in parallel to ddPCR.
For patients enroled prior to prospective targeted sequencing, a banked plasma
sample was sent for retrospective testing, where available. This banked plasma
sample was either remaining plasma banked after prospective ctDNA screening, or
a cycle 1 day 1 (C1D1) pre-treatment plasma sample.
Blood samples for ctDNA testing were collected as described following
enrolment into the ctDNA testing component of the plasmaMATCH trial44. 30–40
ml of blood was collected in 3–4 10 ml cell-free DNA BCT Streck tubes. 30 ml of
blood was shipped at ambient temperature to a central laboratory (Centre for
Molecular Pathology, Royal Marsden Hospital) for ddPCR testing. In addition,
following protocol amendment, 10 ml were shipped to Guardant Health (Redwood
City, California, USA) for targeted sequencing. At the central laboratory, blood
samples were centrifuged at 1600 g for 10 min prior to plasma isolation. This was
followed by a second centrifuge at 1600 g for 10 min, following which the plasma
was aliquoted and stored at −80 ̊C until further analysis. For samples shipped to
Guardant Health, samples were centrifuged at 1600 g for 10 min, and the resulting
supernatant further centrifuged at 3220 g for 10 min. Isolated plasma was stored at
2 ̊C for immediate extraction, or stored at −80 °C.
For patients who underwent retrospective targeted sequencing, remaining
banked plasma from the ctDNA testing or C1D1 time points was thawed at room
temperature. Tubes were inverted 10 times, before a minimum of 2 ml was
aliquoted into a separate 4.5 ml cryovial. Aliquoted plasma was stored at −80 °C
until shipment on dry ice to Guardant Health.
ctDNA testing by targeted sequencing by Guardant360, Guardant Health. The
Guardant360 targeted sequencing panel identifies single nucleotide variants
(SNVs), indels, copy number alterations and fusions within protein-coding regions
of 73 (version 2.10) or 74 genes (version 2.11) (Supplementary Fig. 1b). Plasma was
isolated from whole blood by double centrifugation followed by cell-free DNA
extraction according to the manufacturer’s instructions (QIAamp Circulating
Nucleic Acid Kit, Qiagen) and quantified prior to library preparation. DNA was
labelled with non-random oligonucleotide adaptors (IDT, Inc.), enriched by hybrid
capture (Agilent Technologies, Inc.), pooled, and sequenced using paired-end
synthesis (NextSeq 500 and/or HiSeq 2500, Illumina, Inc.).
ctDNA targeted sequencing bioinformatic analysis, variant detection and
pathogenicity assessment. The Guardant Health in-house custom Guardant360
pipeline is described elsewhere45, but in brief, base calls were demultiplexed using
bcl2fastq (v2.19), filtered for base quality and aligned to hg19 using BWA-MEM.
SNVs, indels, copy number alterations and fusions were detected by comparing
base calls to reference training sets.
The sequencing results generated by Guardant Health underwent further
bioinformatics analysis at the Institute of Cancer Research, UK. Data were
converted to MAF format using vcf2maf (https://github.com/mskcc/vcf2maf) using
MSKCC isoform overrides for annotation with VEP version9646. Additional likely
germline calls based on a combination of VAF frequency around 50%+− 2% and
VAF in general population in the Genome Aggregation Database (https://gnomad.
broadinstitute.org/) >0.001% were removed from the dataset. Pathogenic calls were
identified by the following process: all mutation calls were further annotated with
OncoKB47 and CancerHotspots48 and cross referenced against the Cosmic
database v9049 to identify recurrently reported mutations. Mutations were
classified as pathogenic based on Cancer Hotspots or OncoKB annotations,
recurrent mutations in key breast cancer genes (ESR1, HER2, PIK3CA, EGFR, RB1
and FGFR2) or splicing mutations. MAPK pathway genes included mutations in
the following genes (EGFR, HRAS, KRAS, NRAS, ARAF, BRAF, RAF1, MAP2K1,
MAP2K2, MAPK1, MAPK3, FGFR1, FGFR2 and FGFR3), fusions of FGFR2 and
FGFR3, and copy number changes (CN > 3) in the following genes (BRAF, EGFR,
FGFR1, FGFR2, KRAS). All analyses were based on mutations screened as likely
pathogenic with the exception of mutational signature analysis that included all
mutations regardless of their pathogenicity.
ctDNA testing by droplet digital PCR for plasmaMATCH. Following enrolment
into plasmaMATCH, patients had a blood sample drawn which underwent
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prospective ctDNA testing for hotspot mutations in PIK3CA, ESR1, HER2 and
AKT1 (Supplementary Fig. 1b and Supplementary Table 4, and methodology
previously published44). DNA was extracted from screening plasma using the
automated QiaSymphony platform (Qiagen, Hilden). DNA was quantified by
Qubit (Thermo Scientific) before being combined with singleplex or multiplex
droplet digital PCR (ddPCR) assays targeting hotspot mutations44 (Supplementary
Table 4), supermix and nuclease free water. The samples were partitioned into
droplets using an Automated Droplet Generator (Bio-Rad, Pleasanton) before
undergoing 40 cycles of PCR on a thermal cycler. Results were analysed on a
QX200 Digital Reader (Bio-Rad, Pleasanton). ddPCR assays were considered
positive with a minimum of two positive FAM droplets (mutant) per reaction.
Poisson probability was used to calculate allele frequency (AF).
ctDNA validation testing of PIK3CA and HER2 mutations by droplet digital
PCR. DNA was extracted from screening or pre-treatment C1D1 plasma (to match
the timepoint sequenced by targeted sequencing with Guardant360) using the
automated QiaSymphony platform (Qiagen, Hilden) or manually using the
QIAamp Circulating Nucleic Acid Kit (Qiagen, Hilden) following the manu-
facturer’s instructions. Extracted DNA was quantified by Qubit (Thermo Scientific)
or by Taqman assay droplet digital PCR (ddPCR). Following quantification, DNA
was combined with singleplex ddPCR assays targeting specific mutations (Table 1
and Supplementary Table 4), supermix and nuclease free water before partition
into droplets using an Automated Droplet Generator (Bio-Rad, Pleasanton).
Samples underwent 40 cycles of PCR on a thermal cycler before analysis on a
QX200 Digital Reader (Bio-Rad, Pleasanton). ddPCR assays were considered
positive with one or more positive FAM droplets (mutant) per reaction. Poisson
probability was used to calculate allele frequency (AF).
Cancer fraction. Variant allele frequency (VAF) is dependent on plasma ctDNA
purity, with the number of cancer cells harbouring the mutation relative to all the
cancer cells present, and any copy number alteration affecting the gene50. With the
assumption that the mutation with the highest allele frequency in a sample
represents a truncal mutation present in every cancer cell, the clonality of any other
mutations present can be calculated relative to the mutation with greatest allele
frequency, termed cancer fraction. The cancer fraction was calculated as the allele
frequency of the mutation relative to the maximum somatic VAF (mVAF) present
in the sample. Samples with a single alteration were not assessable for cancer
fraction. Analysis of copy number versus allele frequency revealed that, in this
dataset of patients with metastatic breast cancer, copy number changes had neg-
ligible influence on allele frequency (Supplementary Fig. 16). This allowed for
global comparison across the dataset, nevertheless recognising that for individual
mutations the local copy number status may affect classification. Analyses based on
categorical assessment of clonality, mutations with cancer fraction ≥0.5 were
considered dominant, whilst mutations with cancer fractions <0.5 were considered
subclonal.
HER2 copy number adjustment. The plasma HER2 copy number identified is
influenced by the purity, or amount of tumour DNA relative to normal DNA, of
the sample. To account for this, we adjusted the copy number relative to the mVAF
in the sample using the below formula, as described elsewhere39:
Adjusted pCN ¼ ½Observed pCN-2*ð1 T%Þ=T%
whereT% ¼ 2XmVAFmax=100
pCN ¼ patient Copy Number
Comparison of plasmaMATCH dataset with MSKCC and TCGA datasets. Data
for MSKCC11 dataset was downloaded from cbioportal (https://www.cbioportal.org/).
Metastatic breast cancer samples where the patient phenotype was either HR+HER2-,
HR+HER2+ , HR-HER2+ , or TNBC were included. If a patient had two samples,
the most recent biopsy result was analysed. The TCGA dataset was downloaded from
the Genomic Data Commons Data Portal (https://portal.gdc.cancer.gov/). Only primary
breast cancer samples where the patient phenotype was either HR+HER2-, HR+
HER2+ , HR-HER2+ , or TNBC were included.
Mutation calls from both datasets were annotated using the same ICR
bioinformatics pipeline as the plasmaMATCH dataset (described earlier). Mutation
calls were filtered to only include loci present in both sequencing panels for
comparison and mutations judged to be pathogenic (described earlier). Fisher’s
exact test was used to compare the proportions of gene alterations within each
dataset for each phenotype, with adjustment for multiple testing using the
Benjamini-Hochberg procedure (false discovery rate, FDR).
Mutational signatures. For HR+HER2- and TNBC respectively, somatic
alterations were aggregated into clonal (cancer fraction ≥ 0.5) versus subclonal
alterations. Each mutation site was counted once, however, if a mutation was
differentially classified as clonal and subclonal in different patients, the mutation
was counted in both sets. Signature contributions were estimated using the
deconstructSigs R package51 using a set of 30 mutational signatures from Cosmic52.
Bootstrap sampling to define confidence intervals of assignments was applied
sampling 90% of the data in 200 iterations for each subtype. Signature contribu-
tions for clonal versus subclonal alterations were compared using the Mann-
Whitney U test. Orthogonal analysis was also carried out using SigMA35 with
tumour type breast cancer using exome trinucleotide counts (Supplementary
Fig. 12). For categorical analysis of APOBEC consensus sites the following trinu-
cleotides were included: T(C > G)T, T(C > G)A, T(C > A)[N] on both DNA
strands.
Statistical analyses. Data was collated in Microsoft Excel (2016). Statistical
analysis was carried out using R version 3.5.2 and Graphpad Prism version 8.0.1.
Categorical data was analysed using a Chi-squared test for group-wise analysis, and
pairwise Fisher’s exact test (R package RVAideMemoire) for intergroup compar-
isons. Where indicated with a q value rather than a p value, a correction has been
made for multiple testing using the Benjamini–Hochberg procedure. Continuous
data was compared using the Kruskal–Wallis test, and where a significant finding
was found a pairwise Kruskal–Wallis test (package pairw.kw() function from R
package asbio) was used to identify individual significant differences following
correction for multiple testing based on the Bonferroni procedure. Where data was
paired the Wilcoxon signed-rank test was utilised. Co-occurrence and mutual
exclusivity of gene alterations was assessed using the Fisher’s exact test, with
correction for multiple testing using the Benjamini–Hochberg procedure. Genes
with alterations to an incidence of 5% in the cohort were included. Two-sided p
values have been used throughout. Time to event survival data were analysed with
log-rank test and hazard ratios were calculated with Cox regression. Plots were
created using Microsoft Excel, Graphpad Prism and the R software packages
ggplot2, pheatmap, ggalluvial and survminer.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The processed plasmaMATCH Guardant360 sequencing data generated and analysed
during the current study are available within Supplementary Data 1. We do not have
permission from the patients to publicly deposit the raw sequencing data. To protect the
privacy and confidentiality of patients in this study, clinical data are also not made
publicly available. The data can be obtained by submitting a formal data access request in
accordance with the Institute of Cancer Research Clinical Trials and Statistics Unit (ICR-
CTSU) data and sample access policy. Requests are to be made via a standard proforma
Table 1 PIK3CA and HER2 (ERBB2) mutations identified
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describing the nature of the proposed research and extent of data requirements which is
reviewed by the trial management group. Data recipients are required to enter a formal
data sharing agreement, which describes the conditions for data release and requirements
for data transfer, storage, archiving, publication, and intellectual property. Trial
documentation including the protocol are available on request by contacting
plasmamatch-icrctsu@icr.ac.uk.
The MSKCC data are available in the cBioPortal for Cancer Genomics database
(https://www.cbioportal.org/study/summary?id=breast_msk_2018).
The TCGA data are available in the cBioPortal for Cancer Genomics database (https://
www.cbioportal.org/study/summary?id=brca_tcga_pan_can_atlas_2018). TGCA data
analysed for this manuscript were released 28th January 2016.
All other data are available within the Article, Supplementary Information or available
from the authors upon request.
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